Integrating semaglutide and tirzepatide into your practice can significantly increase patient demand and revenue
Blood sugar improvements, blood pressure reductions, and lipid changes tend to reverse once the medication is discontinued
Cureus Sinha R, Papamargaritis D, Sargeant JA, Davies MJ (2023) Efficacy and safety of tirzepatide in type 2 diabetes and obesity management
By presenting pathway options within a medical decision-making framework, MEDVi reinforces semaglutides role as a clinically managed therapy rather than a consumer commodity
Tirzepatide may produce greater average weight loss for some individuals because it activates two hormone pathways, GLP-1 and GIP, while semaglutide targets only the GLP-1 receptor
Retatrutide, on the other hand, does not just reduce appetite